Sugi Predict

Sugi Predict / Compounds / SCHEMBL2225858

SCHEMBL2225858

SCHEMBL2225858

CC(C)(C)OC(=O)N1CCC[C@@H]1C(N)=O

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ LMNA P02545 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ UCHL1 P09936 2/20 0.48
▸ SCN4A P35499 1/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ SCN5A Q14524 1/20 0.44
▸ SCN3A Q9NY46 1/20 0.44
▸ EPHX2 P34913 1/20 0.44
▸ USP30 Q70CQ3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL239130 1.00 HSD17B10 (0.59) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL240483 1.00 HSD17B10 (0.59) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL1478166 0.95 HSD17B10 (0.55) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL1478184 0.95 HSD17B10 (0.55) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL82116 0.95 HSD17B10 (0.55) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL1398934 0.90 HSD17B10 (0.48) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL29755212 0.90 HSD17B10 (0.48) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL5069216 0.90 HSD17B10 (0.48) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL31638601 0.87 HSD17B10 (0.57) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL2636790 0.87 HSD17B10 (0.57) HSD17B10SMN1; SMN2NPC1LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116693439-A Synthesis method of (R) -N-methyl-1- (pyrrolidine-2-yl) methylamine 南通敏言生物医药科技有限公司 2023-09-05 — — CN claimed
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2026-02-12 — — US disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
US-20250388583-A1 COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION ENGINE BIOSCIENCES PTE LTD (SG) 2025-12-25 — — US disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
EP-4543881-A1 COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION Engine Biosciences Pte. Ltd. (SG) 2025-04-30 — — EP disclosed
US-20070259926-A1 mGluR5 modulators III ASTRAZENECA AB (SE) 2007-11-08 — — US disclosed
US-20070259926-A1 mGluR5 modulators III ASTRAZENECA AB (SE) 2007-11-08 — — US disclosed
US-20070259862-A1 MGluR5 modulators I ASTRAZENECA AB (SE) 2007-11-08 — — US disclosed
US-20070259862-A1 MGluR5 modulators I ASTRAZENECA AB (SE) 2007-11-08 — — US disclosed
US-20070259862-A1 MGluR5 modulators I ASTRAZENECA AB (SE) 2007-11-08 — — US disclosed
US-20070167426-A1 Compounds for the treatment of inflammatory disorders and microbial diseases SCHERING CORPORATION 2007-07-19 — — US disclosed
WO-2007064749-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES SCHERING CORPORATION (US) 2007-06-07 — — WO disclosed
US-20060178366-A1 Compounds for the treatment of inflammatory disorders SCHERING CORPORATION 2006-08-10 — — US disclosed
EP-0300189-B1 New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO (JP) 1994-11-02 — — EP disclosed
EP-0228192-A2 Renin-inhibitory oligopeptides, their preparation and use SANKYO COMPANY LIMITED (JP) 1987-07-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 HSD17B10 2719/4885SMN1; SMN2 1781/4885NPC1 2384/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HSD17B10 2107/4885SMN1; SMN2 2647/4885NPC1 3159/4885
US-20070167426-A1 Compounds for the treatment of inflammatory disorders and microbial diseases MMP12, ADAMTS1, ADAM33 HSD17B10 581/4885SMN1; SMN2 2291/4885NPC1 481/4885
US-20070259862-A1 MGluR5 modulators I GRM5, GRM1, GRIK5 HSD17B10 2742/4885SMN1; SMN2 1207/4885NPC1 705/4885
US-20070259926-A1 mGluR5 modulators III GRM5, GRM3, GRIK5 HSD17B10 2740/4885SMN1; SMN2 1346/4885NPC1 924/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HSD17B10 2107/4885SMN1; SMN2 2647/4885NPC1 3159/4885
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK4 HSD17B10 1867/4885SMN1; SMN2 960/4885NPC1 1765/4885
US-20060178366-A1 Compounds for the treatment of inflammatory disorders MMP12, ADAMTS1, TNF HSD17B10 622/4885SMN1; SMN2 1570/4885NPC1 477/4885
US-20250388583-A1 COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION PKMYT1, PKN1, PRKCB HSD17B10 2211/4885SMN1; SMN2 3904/4885NPC1 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.